Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Europe may soon have a new treatment option for hemophilia A. The EMA's CHMP has recommended marketing authorization for Frehemgo (denecimig, Novo Nordisk), a subcutaneous bispecific antibody that works independently of factor VIII. Indicated for patients with or without inhibitors, it can be dosed as infrequently as once a month — offering a more flexible approach to long-term prophylaxis.
Europe may be on the verge of adding a new option to the hemophilia A treatment landscape. The EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for Frehemgo (denecimig, Novo Nordisk) — a subcutaneous bispecific antibody designed to prevent bleeding episodes in patients with hemophilia A, including those with and without factor VIII inhibitors.
What sets Frehemgo apart is its mechanism: rather than replacing factor VIII directly, it bridges activated factor IX and factor X to mimic the missing cofactor function, enabling clot formation independent of native factor VIII. This is particularly relevant for patients who have developed inhibitors, for whom traditional factor concentrates are ineffective. Dosing flexibility — once weekly, every two weeks, or once monthly via a prefilled pen — adds to its appeal for long-term prophylaxis.
Key Takeaways:
Why it matters: For patients with hemophilia A — especially those with inhibitors who have limited treatment options — Frehemgo could offer a more convenient and effective prophylactic alternative. EU-wide approval would mark a meaningful step forward in expanding access to next-generation hemophilia care.
